{
  "abstract": "Objective To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3 studies and their open-label extension.Methods BE MOBILE 1 (non-radiographic-axSpA) and 2 (radiographic-axSpA) comprised 16-week double-blind placebo-controlled and 36-week maintenance periods. From week 16, all patients received subcutaneous bimekizumab 160 mg every 4 weeks. At week 52, eligible patients could enrol in the open-label extension BE MOVING and continue bimekizumab treatment. Spinal pain (rated on a numerical rating scale from 0 (no pain) to 10 (maximum pain)), morning stiffness (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) average of Q5/6), fatigue (BASDAI Q1; Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue subscale), sleep quality (Medical Outcomes Study (MOS) Sleep Scale Index II), physical function (Bath Ankylosing Spondylitis Functional Index (BASFI)) and HRQoL (36-Item Short Form Survey (SF-36) physical component summary (PCS)/mental component summary (MCS); Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire) were reported to week 104.Results In total, 494/586 (84.3%) patients entered BE MOVING at week 52; 456 completed week 104. Patients reported substantial changes from baseline to week 104 in total spinal pain (−4.3), nocturnal spinal pain (−4.3), morning stiffness (−4.3) and fatigue (BASDAI Q1: −3.4; FACIT-Fatigue: +9.9). Over half reported total and nocturnal spinal pain scores ≤3 at week 104. Similar improvements to week 104 were shown in sleep (MOS-Sleep Scale: +10.2), physical function (BASFI: −2.9) and HRQoL (SF-36 PCS: +12.4; ASQoL: −5.6).Conclusions Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms and their impacts across the full disease spectrum of axSpA over 2 years, underscoring its long-term potential for improving patients’ daily lives.Trial registration numbers NCT03928704, NCT03928743, NCT04436640",
  "authors": [
    {
      "affiliations": [
        "NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK",
        "Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"
      ],
      "name": "Helena Marzo-Ortega"
    },
    {
      "affiliations": [
        "Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain"
      ],
      "name": "Victoria Navarro-Compan"
    },
    {
      "affiliations": [
        "Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA"
      ],
      "name": "Maureen Dubreuil"
    },
    {
      "affiliations": [
        "Swedish Medical Center, Providence St. Joseph Health and University of Washington, Seattle, Washington, USA"
      ],
      "name": "Philip J Mease"
    },
    {
      "affiliations": [
        "Case Western Reserve University, University Hospitals, Cleveland, Ohio, USA"
      ],
      "name": "Marina Magrey"
    },
    {
      "affiliations": [
        "Department of Internal Medicine and Rheumatology, Bielefeld University, Medical School and University Medical Center, Klinikum Bielefeld, Bielefeld, Germany"
      ],
      "name": "Martin Rudwaleit"
    },
    {
      "affiliations": [
        "Department of Rheumatology, Università Cattolica del Sacro Cuore, Roma, Italy",
        "Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"
      ],
      "name": "Maria-Antonietta D’Agostino"
    },
    {
      "affiliations": [
        "Norfolk and Norwich University Hospital NHS Trust, Norwich, UK"
      ],
      "name": "Karl Gaffney"
    },
    {
      "affiliations": [
        "Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA"
      ],
      "name": "Jonathan Kay"
    },
    {
      "affiliations": [
        "UCB, Brussels, Belgium"
      ],
      "name": "Christine de la Loge"
    },
    {
      "affiliations": [
        "UCB, Monheim am Rhein, Germany"
      ],
      "name": "Ute Massow"
    },
    {
      "affiliations": [
        "UCB, Colombes, France"
      ],
      "name": "Vanessa Taieb"
    },
    {
      "affiliations": [
        "UCB, Slough, UK"
      ],
      "name": "Tom Vaux"
    },
    {
      "affiliations": [
        "Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"
      ],
      "name": "Atul Deodhar"
    }
  ],
  "title": "Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies",
  "uid": "64808493-7dbe-54cd-8a37-99714b02f26d"
}